Onvansertib Evidence: Trial Results and Peer-Reviewed Publications

Pancreatic Neoplasms (17)

• NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
  Lancet · 2023 · PMID 37708904 · NCT06736717
• KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
  Cold Spring Harb Perspect Med · 2019 · PMID 29229669 · NCT06736717
• Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
  Nat Commun · 2018 · PMID 27193833 · NCT06736717
• Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
  J Clin Oncol · 2016 · PMID 26169616 · NCT06736717
• Whole genomes redefine the mutational landscape of pancreatic cancer.
  Nature · 2015 · PMID 25719666 · NCT06736717

Colorectal Neoplasms (2)

• Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
  J Clin Oncol · 2025 · PMID 39475591 · NCT03829410
• Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.
  Clin Cancer Res · 2024 · PMID 38231047 · NCT03829410

Lung Neoplasms (1)

• Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer.
  Cancers (Basel) · 2025 · PMID 39941812 · NCT05450965

Leukemia, Myeloid, Acute (1)

• The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
  Theranostics · 2022 · PMID 34646387 · NCT03303339

2025 (2 papers)

1. Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
   Ahn DH, Ridinger M, Cannon TL, et al. · J Clin Oncol · 2025 · Trial result
   PubMed: PMID 39475591 · NCT03829410 · Colorectal Neoplasms
2. Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer.
   Zhang G, Pannucci A, Ivanov AA, et al. · Cancers (Basel) · 2025 · Derived
   PubMed: PMID 39941812 · NCT05450965 · Lung Neoplasms

2024 (1 paper)

1. Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.
   Ahn DH, Barzi A, Ridinger M, et al. · Clin Cancer Res · 2024 · Trial result
   PubMed: PMID 38231047 · NCT03829410 · Colorectal Neoplasms

2023 (1 paper)

1. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
   Wainberg ZA, Melisi D, Macarulla T, et al. · Lancet · 2023 · Background
   PubMed: PMID 37708904 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2022 (1 paper)

1. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
   Hagege A, Ambrosetti D, Boyer J, et al. · Theranostics · 2022 · Derived
   PubMed: PMID 34646387 · NCT03303339 · Leukemia, Myeloid, Acute

2019 (1 paper)

1. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
   Waters AM, Der CJ · Cold Spring Harb Perspect Med · 2019 · Background
   PubMed: PMID 29229669 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2018 (1 paper)

1. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
   Wang J, Hu K, Guo J, et al. · Nat Commun · 2018 · Background
   PubMed: PMID 27193833 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2016 (1 paper)

1. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
   Smith TJ, Bohlke K, Lyman GH, et al. · J Clin Oncol · 2016 · Background
   PubMed: PMID 26169616 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2015 (1 paper)

1. Whole genomes redefine the mutational landscape of pancreatic cancer.
   Waddell N, Pajic M, Patch AM, et al. · Nature · 2015 · Background
   PubMed: PMID 25719666 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2014 (1 paper)

1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
   Rahib L, Smith BD, Aizenberg R, et al. · Cancer Res · 2014 · Background
   PubMed: PMID 24840647 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2013 (1 paper)

1. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
   Von Hoff DD, Ervin T, Arena FP, et al. · N Engl J Med · 2013 · Background
   PubMed: PMID 24131140 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2012 (1 paper)

1. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.
   Biankin AV, Waddell N, Kassahn KS, et al. · Nature · 2012 · Background
   PubMed: PMID 23103869 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2011 (1 paper)

1. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
   Conroy T, Desseigne F, Ychou M, et al. · N Engl J Med · 2011 · Background
   PubMed: PMID 21561347 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2010 (2 papers)

1. Pancreatic cancer.
   Hidalgo M · N Engl J Med · 2010 · Background
   PubMed: PMID 20427809 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms
2. Targeting Polo-like kinase in cancer therapy.
   Degenhardt Y, Lampkin T · Clin Cancer Res · 2010 · Background
   PubMed: PMID 20068088 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2009 (2 papers)

1. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.
   Luo J, Emanuele MJ, Li D, et al. · Cell · 2009 · Background
   PubMed: PMID 19490893 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms
2. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
   Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Background
   PubMed: PMID 19097774 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2006 (1 paper)

1. Polo-like kinase 1 expression is a prognostic factor in human colon cancer.
   Weichert W, Kristiansen G, Schmidt M, et al. · World J Gastroenterol · 2006 · Background
   PubMed: PMID 16237758 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

2005 (1 paper)

1. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications.
   Weichert W, Kristiansen G, Winzer KJ, et al. · Virchows Arch · 2005 · Background
   PubMed: PMID 15785925 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

1999 (1 paper)

1. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck.
   Knecht R, Elez R, Oechler M, et al. · Cancer Res · 1999 · Background
   PubMed: PMID 10383133 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms

1989 (1 paper)

1. Optimal two-stage designs for phase II clinical trials.
   Simon R · Control Clin Trials · 1989 · Background
   PubMed: PMID 2702835 · NCT06736717 (PANCONVA) · Pancreatic Neoplasms